We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Blocked Neurotransmitter Triggers Epilepsy in Rats

By Biotechdaily staff writers
Posted on 14 Aug 2002
Investigators working with rats have found that blocking transport of gamma-aminobutyric acid (GABA), the most important inhibitory neurotransmitter in the central nervous system, caused the animals to develop epilepsy, a disease characterized by rapid and uncontrolled ‘firing' of brain cells. More...
This study was published in the August 1, 2002, issue of the Journal of Neuroscience.

An antisense treatment to reduce expression of the glutamate transporter EAAC1 was used to inhibit movement of GABA into nerve cells. The rats could not synthesize new GABA, so over the course of 10 days, their GABA levels dropped and epileptic symptoms, including staring-freezing episodes and electrographic (EEG) seizures, became apparent. Interfering with other glutamate transporters (called GLAST-1 and GLT-1) found in other types of neurons did not reduce GABA levels or cause epilepsy.

"We have shown that the synthesis and release of GABA depends heavily on transporting glutamate into nerve cells,” said Dr. Jeffrey Rothstein, professor of neurology and neuroscience at Johns Hopkins University (Baltimore, MD, USA; www.jhu.edu) and one of the investigators. "Previously, only glutamate made inside the cell, rather than brought into it, was thought to contribute to GABA manufacture. Getting more glutamate into GABA-producing neurons may help calm the excessive electrical firing of brain cells.”



Related Links:
Johns Hopkins U.

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.